Posted by Michael Wonder on 06 Nov 2023
MHRA authorises Krazati as a treatment for non-small-cell lung cancer in adults
3 November 2023 - Patients with a certain type of advanced or spreading non-small-cell lung cancer could access a new cancer therapy to help treat their condition.
The Medicines and Healthcare products Regulatory Agency has today authorised a new medicine called Krazati (adagrasib), a treatment for a type of non-small-cell lung cancer in adults that has a mutation and produces a rare protein called KRAS G12C.
